ARNS Response to NICE Asthma Guidance

ARNS Response to NICE Asthma Guidance
  • In the UK, 5.4 million people are currently receiving treatment for asthma: 1.1 million children (1 in 11) and 4.3 million adults (1 in 12).
  • The UK has amongst the highest prevalence rates for asthma in Europe, according to the European Community Health Survey
  • Tragically, the National Review of Asthma Deaths  found that two thirds of asthma deaths are preventable with good, basic care.

Asthma is a condition which can be hard to diagnose and without a single absolute test to diagnose, research has shown that under diagnosis and under treatment is a problem.

Becky Sherrington, Chair of ARNS, said “I support the NICE recommendations, although I appreciate that the tests aren’t widely available at the moment, so an investment in training and equipment will be needed in both primary and secondary care.  I believe that this guidance supports better diagnosis and personalised asthma care.”

ARNS members are asked to send any comments they wish to make on NICE Guidance to info@arns.co.uk  which may be included in the ARNS’ response by Monday, 2nd February 2015.

 

Thanks to all of our sponsors


AstraZeneca Boehringer Chiesi NAPP NAH Pfizer